• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HDAC11,代谢紊乱的新兴治疗靶点。

HDAC11, an emerging therapeutic target for metabolic disorders.

机构信息

Department of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.

Department of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.

出版信息

Front Endocrinol (Lausanne). 2022 Oct 20;13:989305. doi: 10.3389/fendo.2022.989305. eCollection 2022.

DOI:10.3389/fendo.2022.989305
PMID:36339432
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9631211/
Abstract

Histone deacetylase 11 (HDAC11) is the only member of the class IV HDAC, and the latest member identified. It is highly expressed in brain, heart, kidney and some other organs, and located in mitochondria, cytoplasm and nuclei, depending on the tissue and cell types. Although studies in HDAC11 total knockout mice suggest its dispensable features for tissue development and life, it participates in diverse pathophysiological processes, such as DNA replication, tumor growth, immune regulation, oxidant stress injury and neurological function of cocaine. Recent studies have shown that HDAC11 is also critically involved in the pathogenesis of some metabolic diseases, including obesity, diabetes and complications of diabetes. In this review, we summarize the recent progress on the role and mechanism of HDAC11 in the regulation of metabolic disorders, with the focus on its regulation on adipogenesis, lipid metabolism, metabolic inflammation, glucose tolerance, immune responses and energy consumption. We also discuss the property and selectivity of HDAC11 inhibitors and their applications in a variety of and models of metabolic disorders. Given that pharmacological and genetic inhibition of HDAC11 exerts a beneficial effect on various metabolic disorders, HDAC11 may be a potential therapeutic target to treat chronic metabolic diseases.

摘要

组蛋白去乙酰化酶 11(HDAC11)是唯一的 IV 类 HDAC 成员,也是最新发现的成员。它在脑、心、肾和其他一些器官中高度表达,并且根据组织和细胞类型,位于线粒体、细胞质和细胞核中。尽管在 HDAC11 基因敲除小鼠中的研究表明其对于组织发育和生命不是必需的,但它参与了多种病理生理过程,如 DNA 复制、肿瘤生长、免疫调节、氧化应激损伤和可卡因的神经功能。最近的研究表明,HDAC11 还在一些代谢性疾病的发病机制中起着关键作用,包括肥胖、糖尿病和糖尿病并发症。在这篇综述中,我们总结了 HDAC11 在调节代谢紊乱中的作用和机制的最新进展,重点介绍了其对脂肪生成、脂质代谢、代谢炎症、葡萄糖耐量、免疫反应和能量消耗的调节作用。我们还讨论了 HDAC11 抑制剂的特性和选择性及其在各种代谢紊乱模型中的应用。鉴于 HDAC11 的药理学和遗传学抑制对各种代谢紊乱都有有益的作用,HDAC11 可能是治疗慢性代谢性疾病的潜在治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/403d/9631211/d803b168fd16/fendo-13-989305-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/403d/9631211/d803b168fd16/fendo-13-989305-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/403d/9631211/d803b168fd16/fendo-13-989305-g001.jpg

相似文献

1
HDAC11, an emerging therapeutic target for metabolic disorders.HDAC11,代谢紊乱的新兴治疗靶点。
Front Endocrinol (Lausanne). 2022 Oct 20;13:989305. doi: 10.3389/fendo.2022.989305. eCollection 2022.
2
The role of HDAC11 in obesity-related metabolic disorders: A critical review.HDAC11 在肥胖相关代谢紊乱中的作用:一项关键性综述。
J Cell Physiol. 2021 Aug;236(8):5582-5591. doi: 10.1002/jcp.30286. Epub 2021 Jan 22.
3
HDAC11 deletion reduces fructose-induced cardiac dyslipidemia, apoptosis and inflammation by attenuating oxidative stress injury.HDAC11 缺失通过减轻氧化应激损伤减少果糖诱导的心脏血脂异常、细胞凋亡和炎症。
Biochem Biophys Res Commun. 2018 Sep 5;503(2):444-451. doi: 10.1016/j.bbrc.2018.04.090. Epub 2018 Jun 29.
4
Programming and Regulation of Metabolic Homeostasis by HDAC11.HDAC11 对代谢稳态的编程和调控。
EBioMedicine. 2018 Jul;33:157-168. doi: 10.1016/j.ebiom.2018.06.025. Epub 2018 Jun 28.
5
HDAC11: a multifaceted histone deacetylase with proficient fatty deacylase activity and its roles in physiological processes.HDAC11:一种多功能组蛋白去乙酰化酶,具有高效的脂肪酸去酰化酶活性,及其在生理过程中的作用。
FEBS J. 2022 May;289(10):2771-2792. doi: 10.1111/febs.15895. Epub 2021 May 7.
6
Development and Pharmacochemical Characterization Discover a Novel Brain-Permeable HDAC11-Selective Inhibitor with Therapeutic Potential by Regulating Neuroinflammation in Mice.开发和药理学特征研究发现一种新型可穿透血脑屏障的 HDAC11 选择性抑制剂,通过调节小鼠神经炎症具有治疗潜力。
J Med Chem. 2023 Dec 14;66(23):16075-16090. doi: 10.1021/acs.jmedchem.3c01491. Epub 2023 Nov 16.
7
Biological function and small molecule inhibitors of histone deacetylase 11.组蛋白去乙酰化酶 11 的生物学功能及小分子抑制剂。
Eur J Med Chem. 2024 Oct 5;276:116634. doi: 10.1016/j.ejmech.2024.116634. Epub 2024 Jun 27.
8
HDAC11 is a novel regulator of fatty acid oxidative metabolism in skeletal muscle.HDAC11 是骨骼肌脂肪酸氧化代谢的一个新型调节因子。
FEBS J. 2021 Feb;288(3):902-919. doi: 10.1111/febs.15456. Epub 2020 Jul 14.
9
HDAC11 is a regulator of diverse immune functions.HDAC11 是多种免疫功能的调节剂。
Biochim Biophys Acta Gene Regul Mech. 2018 Jan;1861(1):54-59. doi: 10.1016/j.bbagrm.2017.12.002. Epub 2017 Dec 6.
10
Histone deacetylase 11 as a key regulator of metabolism and obesity.组蛋白去乙酰化酶 11 作为代谢和肥胖的关键调节因子。
EBioMedicine. 2018 Sep;35:27-28. doi: 10.1016/j.ebiom.2018.08.008. Epub 2018 Aug 17.

引用本文的文献

1
Unraveling the Translational Relevance of β-Hydroxybutyrate as an Intermediate Metabolite and Signaling Molecule.解析β-羟基丁酸作为中间代谢产物和信号分子的转化相关性
Int J Mol Sci. 2025 Jul 30;26(15):7362. doi: 10.3390/ijms26157362.
2
HDAC11 promotes renal fibrosis by induing partial epithelial-mesenchymal transition and G2/M phase arrest in renal epithelial cells.组蛋白去乙酰化酶11通过诱导肾上皮细胞发生部分上皮-间质转化和G2/M期阻滞来促进肾纤维化。
Res Sq. 2025 May 6:rs.3.rs-6523050. doi: 10.21203/rs.3.rs-6523050/v1.
3
Colorectal Cancer: Pathogenesis and Targeted Therapy.

本文引用的文献

1
Molecular mechanisms of histone deacetylases and inhibitors in renal fibrosis progression.组蛋白去乙酰化酶及其抑制剂在肾纤维化进展中的分子机制
Front Mol Biosci. 2022 Sep 6;9:986405. doi: 10.3389/fmolb.2022.986405. eCollection 2022.
2
LncRNA HDAC11-AS1 Suppresses Atherosclerosis by Inhibiting HDAC11-Mediated Adropin Histone Deacetylation.长链非编码 RNA HDAC11-AS1 通过抑制 HDAC11 介导的阿罗汀组蛋白去乙酰化来抑制动脉粥样硬化。
J Cardiovasc Transl Res. 2022 Dec;15(6):1256-1269. doi: 10.1007/s12265-022-10248-7. Epub 2022 May 3.
3
Long Noncoding RNA TFAP2A-AS1 Suppressed Hepatitis B Virus Replication by Modulating miR-933/HDAC11.
结直肠癌:发病机制与靶向治疗
MedComm (2020). 2025 Mar 6;6(3):e70127. doi: 10.1002/mco2.70127. eCollection 2025 Mar.
4
Transcriptional dynamics in type 2 diabetes progression is linked with circadian, thermogenic, and cellular stress in human adipose tissue.2型糖尿病进展过程中的转录动力学与人体脂肪组织中的昼夜节律、产热和细胞应激相关。
Commun Biol. 2025 Mar 8;8(1):398. doi: 10.1038/s42003-025-07709-5.
5
Histone Deacetylase Inhibitors for Peripheral T-Cell Lymphomas.用于外周T细胞淋巴瘤的组蛋白去乙酰化酶抑制剂
Cancers (Basel). 2024 Sep 30;16(19):3359. doi: 10.3390/cancers16193359.
6
Histone deacetylases: potential therapeutic targets for idiopathic pulmonary fibrosis.组蛋白去乙酰化酶:特发性肺纤维化的潜在治疗靶点。
Front Cell Dev Biol. 2024 Aug 13;12:1426508. doi: 10.3389/fcell.2024.1426508. eCollection 2024.
7
In-Cell Testing of Zinc-Dependent Histone Deacetylase Inhibitors in the Presence of Class-Selective Fluorogenic Substrates: Potential and Limitations of the Method.在存在类别选择性荧光底物的情况下对锌依赖性组蛋白去乙酰化酶抑制剂进行细胞内测试:该方法的潜力与局限性
Biomedicines. 2024 May 29;12(6):1203. doi: 10.3390/biomedicines12061203.
8
Rapid Determination of Kinetic Constants for Slow-Binding Inhibitors and Inactivators of Human Histone Deacetylase 8.快速测定人组蛋白去乙酰化酶 8 的缓慢结合抑制剂和失活剂的动力学常数。
Int J Mol Sci. 2024 May 21;25(11):5593. doi: 10.3390/ijms25115593.
9
The Histone Deacetylase Family: Structural Features and Application of Combined Computational Methods.组蛋白去乙酰化酶家族:结构特征及联合计算方法的应用
Pharmaceuticals (Basel). 2024 May 10;17(5):620. doi: 10.3390/ph17050620.
10
Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives.探索组蛋白去乙酰化酶及组蛋白去乙酰化酶抑制剂在多发性骨髓瘤中的作用:作用机制、治疗意义及未来展望
Exp Hematol Oncol. 2024 Apr 23;13(1):45. doi: 10.1186/s40164-024-00507-5.
长链非编码 RNA TFAP2A-AS1 通过调控 miR-933/HDAC11 抑制乙型肝炎病毒复制。
Dis Markers. 2022 Apr 18;2022:7733390. doi: 10.1155/2022/7733390. eCollection 2022.
4
Target Design of Novel Histone Deacetylase 6 Selective Inhibitors with 2-Mercaptoquinazolinone as the Cap Moiety.新型组蛋白去乙酰化酶 6 选择性抑制剂的设计,以 2-巯基喹唑啉酮作为帽结构。
Molecules. 2022 Mar 28;27(7):2204. doi: 10.3390/molecules27072204.
5
Reversible lysine fatty acylation of an anchoring protein mediates adipocyte adrenergic signaling.锚定蛋白赖氨酸可逆脂肪酸酰化介导脂肪细胞肾上腺素能信号转导。
Proc Natl Acad Sci U S A. 2022 Feb 15;119(7). doi: 10.1073/pnas.2119678119.
6
Association of DNA methylation and transcriptome reveals epigenetic etiology of heart failure.DNA 甲基化与转录组关联揭示心力衰竭的表观遗传病因。
Funct Integr Genomics. 2022 Feb;22(1):89-112. doi: 10.1007/s10142-021-00813-9. Epub 2021 Dec 6.
7
11β-Hydroxysteroid dehydrogenase 2: A key mediator of high susceptibility to osteoporosis in offspring after prenatal dexamethasone exposure.11β-羟类固醇脱氢酶 2:产前地塞米松暴露后后代骨质疏松症高易感性的关键介质。
Pharmacol Res. 2022 Jan;175:105990. doi: 10.1016/j.phrs.2021.105990. Epub 2021 Nov 19.
8
Antitumor activity of novel POLA1-HDAC11 dual inhibitors.新型 POLA1-HDAC11 双重抑制剂的抗肿瘤活性。
Eur J Med Chem. 2022 Jan 15;228:113971. doi: 10.1016/j.ejmech.2021.113971. Epub 2021 Nov 3.
9
Sugar-Sweetened Beverage, Diet Soda, and Nonalcoholic Fatty Liver Disease Over 6 Years: The Framingham Heart Study.6年期间的含糖饮料、无糖汽水与非酒精性脂肪性肝病:弗雷明汉心脏研究
Clin Gastroenterol Hepatol. 2022 Nov;20(11):2524-2532.e2. doi: 10.1016/j.cgh.2021.11.001. Epub 2021 Nov 6.
10
The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma.EGFR 和 ERBB2 突变型肺腺癌的免疫微环境。
ESMO Open. 2021 Oct;6(5):100253. doi: 10.1016/j.esmoop.2021.100253. Epub 2021 Sep 3.